Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01395030 · ClinicalTrials.gov registry record · Phase 2
PET/CT in Diagnosing Patients With Liver Cancer Undergoing Surgical Resection
A Phase 2 study, sponsored by Queen's Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT01395030 is a Phase 2 study that has completed, run by Queen's Medical Center. The registered enrollment target is 64 participants.
The verdict
NCT01395030, a Phase 2 study, has completed, sponsored by Queen's Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
This clinical trial studies positron emission tomography (PET)/computed tomography (CT) in diagnosing patients with liver cancer undergoing surgical resection. Diagnostic procedures, such as fluorine-18 fluoromethylcholine PET/CT, may help find and diagnose liver cancer.
Interventions
- DIAGNOSTIC_TEST Computed Tomography
- DIAGNOSTIC_TEST Positron Emission Tomography
- DRUG 18F-fluoromethylcholine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2011-08-15 |
| Est. Completion | 2018-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01395030
The ClinicalTrials.gov registry entry for NCT01395030 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Queen's Medical Center, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Computed Tomography is the first listed.
NCT01395030 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01395030 about?
NCT01395030 is a clinical study titled "PET/CT in Diagnosing Patients With Liver Cancer Undergoing Surgical Resection". This clinical trial studies positron emission tomography (PET)/computed tomography (CT) in diagnosing patients with liver cancer undergoing surgical resection. Diagnostic procedures, such as fluorine-18 fluoromethylcholine PET/CT, may help find and diagnose liver cancer.
What is the current status of trial NCT01395030?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2011-08-15. Estimated completion is 2018-05-31.
What interventions are being tested in trial NCT01395030?
The interventions under investigation include: Computed Tomography (DIAGNOSTIC_TEST), Positron Emission Tomography (DIAGNOSTIC_TEST), 18F-fluoromethylcholine (DRUG).
Who is sponsoring clinical trial NCT01395030?
This trial is sponsored by Queen's Medical Center, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.